Full-Time

Manager of Sales

Data Analytics

Posted on 11/22/2025

Sartorius

Sartorius

5,001-10,000 employees

Laboratory instruments and bioprocess solutions

No salary listed

Remote in UK

Remote

Category
Sales & Account Management (1)
Data & Analytics (1)
Required Skills
Sales
Lead Generation
Marketing
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Academic degree in Business Administration, Marketing, Bioprocess or Data Analytics or relevant field
  • Sales experience with selling software, not only license but larger enterprise engagements
  • Experience in the pharmaceutical, biopharmaceutical or biotechnology industry
  • Understanding data analytics solutions and their applications within the Life Science industry
  • Experience with SFDC and sales analytics tools and other CRMs
  • Experience of managing a team, the ability to inspire and drive performance
  • Strong communication and negotiation skills
  • Ability to analyse market data and trends to make strategic decisions
  • Ability to effectively present technical information
  • Interpersonal skills and ability to build relationships with stakeholders of all organisational levels
  • Strong problem solving and organisational skills
  • MS Office skills (Excel, PowerPoint)
  • Right to work in the United Kingdom or Sweden
Responsibilities
  • Develop and implement the sales strategy within an assigned area of responsibility and drive and monitor sales results within this area
  • Actively use SFDC to manage and document leads and opportunities, all customer interactions and sales activities ensuring that all customer and opportunity information is up-to-date and accurately entered in the CRM system
  • Analyze SFDC data for assigned customers to identify trends, generate customer insights and track sales performance
  • Build and maintain an efficient sales teams to achieve business objectives and customer satisfaction across their area of responsibility
  • Manage the regional Data Analytics sales implementation, lead identification, strategic evaluation, selling cycle, resulting disposable business and financial solution of our Integrated Solutions offering
  • Acquire new and expand the relationships with existing customers by continuously proposing solutions that meet their objectives
  • Provide pre-sales support and expertise to assist the sales team in their sales effort
  • Deliver presentations and product demonstrations to clients and sales representatives
  • Collaborate with all stakeholders in the organization and serve as the link of communication between key customers and internal teams
  • Provide ad hoc and regular reports of progress and forecasts to internal and external stakeholders using key account metrics
  • Identify opportunities to improve market coverage
  • Provide insights for customer support to address clients' issues in the usage of organizational products and services
  • Represent the company at meetings / events / gatherings / Industry Interest groups
Desired Qualifications
  • Sales experience with selling software, not only license but larger enterprise engagements
  • Experience in the pharmaceutical, biopharmaceutical or biotechnology industry
  • Understanding data analytics solutions and their applications within the Life Science industry
  • Experience with SFDC and sales analytics tools and other CRMs
  • Experience of managing a team, the ability to inspire and drive performance
  • Strong communication and negotiation skills
  • Ability to analyse market data and trends to make strategic decisions
  • Ability to effectively present technical information
  • Interpersonal skills and ability to build relationships with stakeholders of all organisational levels
  • Strong problem solving and organisational skills
  • MS Office skills (Excel, PowerPoint)
  • Academic degree in Business Administration, Marketing, Bioprocess or Data Analytics or relevant field

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Simplify Jobs

Simplify's Take

What believers are saying

  • Goldman Sachs upgrades Sartorius Stedim Biotech to Buy rating.
  • Sartorius achieves 3.5 billion euros sales revenue in 2025.
  • Management forecasts 5-9% sales growth for 2026 with MATTEK contributions.

What critics are saying

  • Thermo Fisher undercuts Sartorius bioreactors, capturing 15-20% market share.
  • Danaher's Cytiva launches Sartocon competitor with 30% higher throughput.
  • Chinese clones replicate Arium Mini at 40% lower cost, eroding Asia sales.

What makes Sartorius unique

  • Sartorius launches Arium Mini Extend for versatile Type 1 water dispensing.
  • Sartorius opens $100M Bioanalytics CoE in Ann Arbor, Michigan.
  • Sartorius partners with Sanofi on downstream process intensification.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Sartorius who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

Sartorius AG
May 6th, 2026
Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.

The Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.

Yahoo Finance
Feb 3rd, 2026
Sartorius grows revenue 7.6% to €3.5B with EBITDA margin expanding to 29.7%

Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.

Yahoo Finance
Feb 3rd, 2026
Sartorius Stedim Biotech posts 18% profit growth despite equipment softness, cuts debt ratio to 3.55

Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.

Firmenpresse
Sep 16th, 2025
Repairon secures funding for heart therapy

Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.

INACTIVE